Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20436503.
- Also identified by DOI 10.1038/modpathol.2010.55.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There are currently three prognostic/predictive biomarkers used in routine clinical management of patients with breast cancer, and their assessment is mandatory. They include estrogen receptor-alpha (ERalpha), progesterone receptor (PgR), and the HER2 oncogene/oncoprotein. This paper briefly reviews the assessment of ERalpha, PgR, and HER2 in breast cancer, emphasizing recent progress and persistent controversies.
Medical subject headings
- Biomarkers, Tumor
- Breast Neoplasms
- Estrogen Receptor alpha
- Erb-b2 Receptor Tyrosine Kinases